Spots Global Cancer Trial Database for myeloproliferative disorder
Every month we try and update this database with for myeloproliferative disorder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms | NCT03808805 | Myeloproliferat... Aquagenic Pruri... | Aprepitant 80 m... Hydroxyzine 25m... Placebo of Hydr... Placebo of Apre... | 18 Years - | University Hospital, Brest | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | NCT00588666 | Myeloproliferat... Urothelial Carc... Cancer | Bevacizumab Carboplatin Gemcitabine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia | NCT06246006 | Myeloproliferat... | Gene sequencing | 18 Years - 99 Years | Centre Hospitalier Universitaire de Nīmes | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | NCT01611298 | Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Hodgkin Lymphom... Non-Hodgkin Lym... | Tetanus | 3 Years - 70 Years | Baylor College of Medicine | |
| Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | NCT00722254 | Primary Myelofi... Primary Pulmona... Secondary Myelo... Pulmonary Arter... | 18 Years - | University of Utah | ||
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | NCT03852407 | Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom... | Thymoglobulin Melphalan Fludarabine Cyclophosphamid | 18 Years - 75 Years | University of Liege | |
| Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | NCT00722254 | Primary Myelofi... Primary Pulmona... Secondary Myelo... Pulmonary Arter... | 18 Years - | University of Utah | ||
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | NCT03734601 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Lymphoc... B-cell Lymphoma T-cell Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myelomo... | Total body irra... Anti-thymocyte ... Tacrolimus Mycophenolate m... Total lymphoid ... | 18 Years - | Stanford University | |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | NCT03480360 | Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Myelodysplasia Myeloproliferat... Myelofibrosis Lymphoma Lymphoma, Non-H... Plasma Cell Dis... | Cyclophosphamid... Fludarabine Total Body Irra... Tacrolimus cellcept g-csf Peripheral Bloo... | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms | NCT03688490 | Myeloproliferat... | - | University Hospital, Brest | ||
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | NCT03734601 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Lymphoc... B-cell Lymphoma T-cell Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myelomo... | Total body irra... Anti-thymocyte ... Tacrolimus Mycophenolate m... Total lymphoid ... | 18 Years - | Stanford University | |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | NCT01611298 | Acute Lymphobla... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Hodgkin Lymphom... Non-Hodgkin Lym... | Tetanus | 3 Years - 70 Years | Baylor College of Medicine | |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | NCT00858572 | AML CML MDS Myeloproliferat... | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms | NCT03808805 | Myeloproliferat... Aquagenic Pruri... | Aprepitant 80 m... Hydroxyzine 25m... Placebo of Hydr... Placebo of Apre... | 18 Years - | University Hospital, Brest | |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | NCT03734601 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Lymphoc... B-cell Lymphoma T-cell Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myelomo... | Total body irra... Anti-thymocyte ... Tacrolimus Mycophenolate m... Total lymphoid ... | 18 Years - | Stanford University | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. | NCT03869476 | Myeloproliferat... Essential Throm... Primary Myelofi... Primary Myelofi... | Non-invasive di... | 18 Years - 99 Years | University Hospital, Angers | |
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia | NCT06246006 | Myeloproliferat... | Gene sequencing | 18 Years - 99 Years | Centre Hospitalier Universitaire de Nīmes | |
| Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | NCT03434730 | Acute Myeloid L... Acute Lymphobla... Acute Leukemia Myelodysplastic... Myelodysplastic... Myeloproliferat... Non Hodgkin Lym... Hodgkin Lymphom... Leukemia | Total Body Irra... Cyclosporine Mycophenolate M... Tocilizumab Filgrastim | 18 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | NCT00858572 | AML CML MDS Myeloproliferat... | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
